Departments of Neuroscience and Neurology, University of Connecticut School of Medicine, Farmington, CT, USA.
Departments of Neuroscience and Neurology, University of Connecticut School of Medicine, Farmington, CT, USA.
Curr Opin Pharmacol. 2022 Apr;63:102184. doi: 10.1016/j.coph.2022.102184. Epub 2022 Feb 18.
Recent studies have implicated cellular senescence as a disease-related process linked to progressive forms of multiple sclerosis (MS). Herein, we present an overview of the current pharmacopeia of cellular senescence affecting compounds and evidence for their effects, if known, in murine and cellular models of MS. Consideration is also given to the utility of these compounds for the treatment of progressive MS, with an examination of past and current clinical trials that have tested these agents, often for other purposes, in the MS patient population. Lastly, we discuss the implications and potential utility for targeting cellular senescence as a strategy to fulfil the unmet need of treatment options for the progressive MS population.
最近的研究表明，细胞衰老作为一种与多发性硬化症（MS）进行性形式相关的疾病相关过程。在此，我们概述了影响细胞衰老的化合物的药理学现状及其在 MS 小鼠和细胞模型中的作用证据（如果已知的话）。还考虑了这些化合物在治疗进行性 MS 中的效用，检查了过去和目前的临床试验，这些试验通常出于其他目的，在 MS 患者群体中测试了这些药物。最后，我们讨论了将细胞衰老作为一种策略的意义和潜在效用，以满足进行性 MS 人群对治疗选择的未满足需求。
